Across 3 studies, all reported beneficial effects on liver function, with effect sizes ranging from small to moderate (predominantly moderate). The evidence primarily comes from review articles and one animal study; no human clinical trials with extractable dose or form data were identified. The small evidence base warrants caution.
Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 3 studies) — conclusions should be considered preliminary. None of the included studies reported statistically significant findings, so the effect may be smaller than the predominant direction suggests. Moreover, two studies are review articles that may not specifically address Lactobacillus brevis SBC8803, and one study used a different strain (Lactobacillus fermentum LA12), limiting direct applicability.
This review analyzes the effects of gut microbiome modulation on the course of CLD, by using pharmacotherapy, nutrition, fecal microbiota transplantation, supplements, and probiotics.
probiotic therapy as a safe, inexpensive and a noninvasive strategy can reduce pathophysiological symptoms and improve different types of liver diseases without side effects
Serum and hepatic analyses also revealed that the restoration of epithelial barrier function may prevent the leakage of endotoxin into the blood, subsequently improve liver function and hepatic steatosis in the L. fermentum LA12-treated rats.